Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise

Integrative Cancer Therapies

Volumn 8, Issue 1, 2009, Pages 17-21

  Wonders, Karen Y ^a   Reigle, Beverly S ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cardioprotection; Cardiotoxicity; Doxorubicin; Exercise; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXERCISE; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPOTENSION; LIFESTYLE MODIFICATION; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TACHYCARDIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DOXORUBICIN; EXERCISE THERAPY; FEMALE; HEART DISEASES; HUMANS;

EID: 61849096203     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735408330717     Document Type: Review

References (62)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society ; 2008.
2. National Comprehensive Cancer Network & American Cancer Society. Breast Cancer: Treatment Guidelines for Patients. Jenkintown, PA: National Comprehensive Cancer Network & American Cancer Society ; 2007.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer 2006. http://www.nccn.org/professionals/physician- gls/PDF/breast.pdf Accessed November 14, 2007.
4. Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin. Cancer. 2003 ; 97: 2869-2879.
5. Goldhirsch A., Coates AS, Gelber RD, Glick JH, Thurlimann B., Senn HJ First select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006 ; 17: 1772-1776.
6. Combs AB, Hudman SL, Bonner HW Effect of exercise stress upon the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol. 1979 ; 23: 395-398.
7. Wonders KY, Hydock DS, Schneider CM, Hayward R. Acute exercise protects against doxorubicin cardiotoxicity. Integr Cancer Ther. 2008 ; 7: 147-154.
8. Kanter MM, Hamlin RL, Unverferth DV, et al. Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol. 1985 ; 59: 1298-1303.
9. Ascensao A., Magalhaes J., Soares JM Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol. 2005 ; 100: 451-460.
10. Ascensao A., Magalhaes J., Soares JM, et al. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol. 2005 ; 289: H722 - H731.
11. Chicco AJ, Hydock DS, Schneider CM, et al. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2005 ; 100: 519-527.
12. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 2006 ; 289: R424 - R431.
13. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol. 2006 ; 47: 182-189.
14. Seidman A., Hudis C., Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002 ; 20: 1215-1221.
15. Baselga J. Herceptin« alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology. 2001 ; 61: 14-21.
16. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990 ; 61: 203-212.
17. Samantha A., LeVea CM, Dougall WC, et al. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A. 1994 ; 91: 1711-1715.
18. van der Greer P., Hunter T., Lindgerg RA, et al. Receptor protein tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994 ; 10: 251-337.
19. Longva KE, Pedersen NM, Haslekas C., et al. Trastuzumab-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer. 2005 ; 116: 359-367.
20. Holbro T., Beerli RR, Maurer F. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003 ; 100: 8933-8938.
21. Hynes NE, Stern DF The biology of erbB2/neu/HER-2 and its role in cancer. Biochem Biophys Acta. 1994 ; 1198: 165-184.
22. Cook-Burns N. Retrospective analysis of the safety of Herceptin« immunotherapy in metastatic breast cancer. Oncology. 2001 ; 61: 58-66.
23. Feldman AM, Lorell BH, Reis SE Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation. 2000 ; 102: 272-274.
24. Carter P., Presta L., Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992 ; 89: 4285-4289.
25. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of Herceptin (trastuzumab). Semin Oncol. 1999 ; 26: 60-70.
26. Goldenberg MM Trastuzumab, a recombinant DNA-derived humanized monocolonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999 ; 21: 309-318.
27. Winer EP, Burstein HJ New combinations with Herceptin« in metastatic breast cancer. Oncology. 2001 ; 61: 50-57.
28. Ravin PM Should HER2 status be routinely measured for all breast cancer patients ? Semin Oncol. 1999 ; 26: 117-123.
29. Pegram MD, Lipton A., Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 ; 16: 2659-2671.
30. Cummings J., Anderson L., Willmott N., et al. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer. 1991 ; 27: 532-535.
31. Le Cesne A., Judson I., Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 ; 18: 2676-2684.
32. Romond EH, Perez EA, Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 1995 ; 353: 1673-1684.
33. Rayson D., Richel D., Chia S., Jackisch C., van der Vegt S., Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol. 2008 ; 19: 1530-1539.
34. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004 ; 22: 322-329.
35. Singal PK, Li T., Kumar D., et al. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000 ; 207: 77-85.
36. Ferrens VJ, Clark JR, Zhang J., et al. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia. 1997 ; 39: 928-937.
37. Singal PK, Deally CM, Weinberg LE Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 ; 19: 817-828.
38. Zucchi R., Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents. 2003 ; 3: 151-171.
39. Conklin KA Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005 ; 4: 110-130.
40. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002 ; 99: 8880-8885.
41. Kuramochi Y., Cote GM, Guo X., et al. Cardiac endothelial cells regulate reactive oxygen species induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling. J Biol Chem. 2004 ; 279: 51141-51147.
42. Dimayuga FO, Ding Q., Keller JN, Marchionni MA, Seroogy KB, Bruce-Keller AJ The neuregulin GGF2 attenuates free radical release from activated microglial cells. Neuroimmunology. 2003 ; 136: 67-74.
43. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol. 2002 ; 29: 22-28.
44. Sawyer DB, Zuppinger C., Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for herceptin-induced cardiotoxicity. Circulation. 2002 ; 105: 1551-1554.
45. Lim CC, Zuppinger C., Guo X., et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004 ; 279: 8290-8299.
46. Doroshow JH, Johasz A., Matsumoto L., et al. Reactive oxygen metabolism induced by trastuzumab (Herceptin) in human breast cancer cells. Proc Am Assoc Cancer Res. 2001 ; 47: 772-781.
47. Tari AM, Lopez-Berestein G. Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2 overexpressing cells, respectively. Int J Cancer. 2000 ; 86: 295-297.
48. Clark AS, West K., Streicher S., et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002 ; 1: 707-717.
49. American Heart Association. Exercise and fitness. http://www. americanheart.org/presenter.jhtml?identifier=1200013. Accessed November 18, 2007.
50. Mock V., Burke MB, Sheehan P., et al. A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 1994 ; 21: 899-907.
51. Mock V., Dow KH, Meares CJ, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997 ; 24: 991-1000.
52. Mock V., Pickett M., Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 2001 ; 9: 119-127.
53. Mock V., Frangakis C., Davidson NE, et al. Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology. 2005 ; 14: 464-477.
54. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003 ; 21: 1660-1668.
55. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer. 2007 ; 110: 918-925.
56. Holmes MD, Chem WY, Feskanich D., et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 ; 293: 2479-2486.
57. Clark CA, Purdie DM, Glaser SL Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer. 2006 ; 6: 170.
58. Jones LW, Courneya KS, Fairey AS, et al. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med. 2004 ; 28: 105-113.
59. Caldarera CM, Guarnieri C., Lazzari F. Catalase and peroxidase activity of cardiac muscle. Boll Soc Ital Biol Sper. 1973 ; 49: 72-77.
60. Powers SK, Demirel HA, Vincent HK, et al. Exercise training improves myocardial tolerance to in vivo ischemia-reperfusion in the rat. Am J Physiol. 1998 ; 275: R1468 - R1477.
61. Husain K., Somani SM Response of cardiac antioxidant system to alcohol and exercise training in the rat. Alcohol. 1997 ; 14: 301-307.
62. Peng X., Chen B., Lim CC, Sawyer DB The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv. 2005 ; 5: 163-171.